Search Result

Results for "

DAR

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (3) ADC Linker (1) Adenosine Receptor (2) Adrenergic Receptor (8) Antibody-Drug Conjugates (ADCs) (5) Apoptosis (1) Bacterial (2) Chloride Channel (1) Dopamine Receptor (5) Drug-Linker Conjugates for ADC (2) E1/E2/E3 Enzyme (1) E3 Ligase Ligand-Linker Conjugates (1) Fluorescent Dye (1) Interleukin Related (1) Isotope-Labeled Compounds (1) Microtubule/Tubulin (2) PERK (1) Reference Standards (4) Small Interfering RNA (siRNA) (8) Topoisomerase (3) YAP (1)
By Research Areas:	Cancer (12) Cardiovascular Disease (2) Endocrinology (6) Inflammation/Immunology (1) Metabolic Disease (1) Neurological Disease (7)
Click Chemistry:	Alkynes (1)
Oligonucleotides:	Rat Pre-designed siRNA Sets (2) Mouse Pre-designed siRNA Sets (2) Human Pre-designed siRNA Sets (4) siRNAs (8)

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Inhibitory Antibodies

Recombinant Proteins

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-164152A

*ADC Control Human IgG1-Deruxtecan (DAR* 8)**	Antibody-Drug Conjugates (ADCs) Topoisomerase	Cancer
ADC Control Human IgG1-Deruxtecan (DAR 8) is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-Deruxtecan and can inhibit DNA topoisomerase I. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E) .

HY-P99542

Tusamitamab ravtansine SAR-408701; HuMAb2-3-SPDB-DM4	Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin	Cancer
Tusamitamab ravtansine (SAR-408701) is a targeted ADC against tumor cells expressing CEACAM5, composed of a humanized anti-CEACAM5 monoclonal antibody covalently linked to the potent cytotoxic agent, maytansinoid DM4 (HY-12454), via a cleavable linker. Tusamitamab ravtansine has an average drug-to-antibody ratio (DAR) of 3.8 .

HY-164152

*ADC Control Human IgG1-Deruxtecan (DAR* 4)**	Antibody-Drug Conjugates (ADCs) Topoisomerase	Cancer
ADC Control Human IgG1-Deruxtecan (DAR 4) is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-Deruxtecan and can inhibit DNA topoisomerase I. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E) .

HY-145448

MC-VC-PABC-amide-PEG1-CH2-CC-885	E3 Ligase Ligand-Linker Conjugates	Cancer
MC-VC-PABC-amide-PEG1-CH2-CC-885 (compound I-1) is a neoDegrader-Linker conjugate, consists of the GSPT1 degrader/molecular glue CC-885 (HY-101488) and a linker. MC-VC-PABC-amide-PEG1-CH2-CC-885 can be conjugated to the antibody DAR3.7 that specifically targets CD56 to synthesize Antibody-Drug Conjugates (ADCs) .

HY-10122

Silodosin 5 Publications Verification KAD 3213; KMD 3213	Adrenergic Receptor Bacterial	Endocrinology Cancer
Silodosin (KAD 3213; KMD 3213) is a potent, selective and orally active α1A-adrenergic receptor (α1A-AR) blocker. Silodosin exhibits high affinity for α1A-AR (K_i=0.036 nM), over 162-fold and 50-fold than for α1B-AR and α1D-AR with K_i values of 21 nM and 2.0 nM, respectively. Silodosin is an effective and well-tolerated agent, it can be used for the investigation of LUTS/BPH .

HY-P99829

Cofetuzumab pelidotin PF-06647020; ABBV-647; h6M24-vc0101	Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin	Cancer
Cofetuzumab pelidotin (PF-06647020) is a PTK7-targeting ADC comprising a humanized anti-PTK7 mAb (hu6M024, IgG1) joined to an auristatin microtubule inhibitor payload, auristatin-0101 (Aur0101; HY-12522), by a cleavable valine-citrulline (vc)-based linker. Cofetuzumab pelidotin has a DAR of 4. Cofetuzumab pelidotin binds to cell-surface PTK7 with an EC₅₀ of 1153 pM by flow cytometry. Cofetuzumab pelidotin has the potential for solid tumors research .

HY-101299B

Dihydrexidine hydrochloride 5 Publications Verification DAR-0100 hydrochloride	Dopamine Receptor	Neurological Disease
Dihydrexidine hydrochloride (DAR-0100 hydrochloride) is a high potent, selective and full efficacy D1-like dopamine receptor (D1/D5) agonist, with an IC₅₀ of 10 nM for D1 receptor. Dihydrexidine hydrochloride exhibits potent antiparkinsonian activity . Dihydrexidine hydrochloride can stimulate YAP phosphorylation .

HY-100554

BMY 7378 2 Publications Verification	Adrenergic Receptor 5-HT Receptor	Cardiovascular Disease
BMY 7378 is a selective antagonist of α_1D-adrenoceptor (α_1D-AR). BMY 7378 binds to membranes expressing the cloned rat α_1D-AR with a >100-fold higher affinity (K_i=2 nM) than binding to either the cloned rat α_1A-AR (K_i=800 nM) or the hamster α_1B-AR (K_i=600 nM). BMY 7378 is a 5-HT_1A receptor partial agonist .

HY-101300

Cirazoline hydrochloride LD 3098 hydrochloride	Adenosine Receptor	Neurological Disease
Cirazoline hydrochloride (LD 3098 hydrochloride) is a potent competitive full α1A-adrenergic receptor (α1A-AR) agonist (K_i=120 nM) and only a partial agonist at α1B-AR (K_i= 960 nM) and α1D-AR (K_i=660 nM) .

HY-163099

P5(PEG24)-VC-PAB-Exatecan	Drug-Linker Conjugates for ADC Topoisomerase Apoptosis	Cancer
P5 (PEG24)-VC-PAB-Exatecan is a TOP1 inhibitor payload with antibody-conjugation-dependent activity. Conjugation of P5 (PEG24)-VC-PAB-Exatecan with Trastuzumab (HY-P9907) generates a *DAR8* antibody-drug conjugate (ADCs) with antibody-like pharmacokinetic properties. P5 (PEG24)-VC-PAB-Exatecan induces S-phase and G2-M-phase cell cycle arrest, DNA damage and apoptosis in target-positive tumor cells, and releases damage-associated molecular patterns (DAMP) related to immunogenic cell death (ICD). The ADCs prepared from it exert bystander killing effects on non-target tumor cells. ADCs based on P5 (PEG24)-VC-PAB-Exatecan exhibit linker stability in vitro and in vivo, show in vivo efficacy, and can be used in research related to HER2-positive cancers .

HY-175888

APL-1082 Mc-exo-EVC-Exatecan	Drug-Linker Conjugates for ADC	Cancer
APL-1082 is a drug-Linker conjugate that can be used for ADC synthesis. APL-1082 contains Exatecan (HY-13631) and Linker (HY-175929). APL-1082 reduces aggregation and hydrophobicity in Trastuzumab (HY-P9907) ADCs, enables production of high-DAR (10) ADCs with homogeneity and defined physicochemical properties. APL-1082 forms a Trastuzumab ADC with enhanced stability, showing greater DAR retention over time. APL-1082 can be used for the research of gastric cancer .

HY-136884

DAR-4M	Fluorescent Dye	Others
DAR-4M is a fluorescent indicator for nitric oxide (NO) based on the rhodamine chromophore (Ex/Em= 550/572 nm) .

HY-101299A

Dihydrexidine DAR-0100	Dopamine Receptor YAP	Neurological Disease
Dihydrexidine (DAR-0100) is a high potent, selective and full efficacy D1-like dopamine receptor (D1/D5) agonist with an IC₅₀ of 10 nM for D1 receptor. Dihydrexidine exhibits potent antiparkinsonian activity . Dihydrexidine can stimulate YAP phosphorylation .

HY-RS03533

DARS2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
DARS2 Human Pre-designed siRNA Set A contains three designed siRNAs for DARS2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

DARS2 Human Pre-designed siRNA Set A DARS2 Human Pre-designed siRNA Set A

HY-156299

NMS-P945	ADC Linker	Cancer
NMS-P945 is an ADC linker that can be used in the synthesis of antibody-drug conjugates (ADCs). NMS-P945 is suitable for conjugation to mAbs with reproducible Drug Antibody Ratio (DAR) >3.5 .

HY-101299

(+)-Dihydrexidine hydrochloride (+)-DAR-0100 hydrochloride	Dopamine Receptor	Neurological Disease
(+)-Dihydrexidine hydrochloride ((+)-DAR-0100 hydrochloride) is a dopamine D1 receptor agonist with an EC₅₀ of 72± 21 nM.

HY-175504

MLS6357	Dopamine Receptor PERK	Neurological Disease
MLS6357 is a D3 dopamine receptor (D3R)-selective positive allosteric modulator (PAM)-antagonist. MLS6357 exhibits antagonist activity in the D3R-mediated and the BRET-based β-arrestin recruitment assay with IC₅₀s of 13 and 14 μM, and no activity for other DAR subtypes (D1R/D2R/D4R/D5R) (IC₅₀ > 100 μM). MLS6357 is also an antagonist in the D3R-mediated Go-BRET assay with an IC₅₀ of 17 μM. MLS6357 can be used for the study of neuropsychiatric disorders, including substance use disorder .

HY-141599

Camidanlumab tesirine ADCT 301	Antibody-Drug Conjugates (ADCs) Interleukin Related	Cancer
Camidanlumab tesirine (ADCT 301) is an ADC comprising HuMax-TAC, a human IgG1 mAb directed against human CD25, stochastically conjugated through a dipeptide cleavable linker to a pyrrolobenzodiazepine (PBD) dimer warhead. Camidanlumab tesirine has a drug–antibody ratio (DAR) of 2.3. Camidanlumab tesirine binds human CD25 with picomolar affinity. Camidanlumab tesirine has highly potent and selective cytotoxicity against a panel of CD25-expressing human lymphoma cell lines .

HY-175669

ANO1-IN-5	Chloride Channel	Metabolic Disease Endocrinology
ANO1-IN-5 is an orally active ANO1 inhibitor with an IC₅₀ of 4.57 μM. J ANO1-IN-5 demonstrates 118-, 642-, and 10000-fold selectivity over α_1A-,α_1B-, andα_1D-AR, respectively. ANO1-IN-5 exhibits significant inhibitory effects on osteoclast differentiation and function. ANO1-IN-5 can used for the study of osteoporosis .

HY-RS27417

Dars1 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Dars1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Dars1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Dars1 Rat Pre-designed siRNA Set A Dars1 Rat Pre-designed siRNA Set A

HY-RS03532

DARS1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
DARS1 Human Pre-designed siRNA Set A contains three designed siRNAs for DARS1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

DARS1 Human Pre-designed siRNA Set A DARS1 Human Pre-designed siRNA Set A

HY-RS21545

Dars2 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Dars2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Dars2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Dars2 Mouse Pre-designed siRNA Set A Dars2 Mouse Pre-designed siRNA Set A

HY-RS20900

Dars1 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Dars1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Dars1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Dars1 Mouse Pre-designed siRNA Set A Dars1 Mouse Pre-designed siRNA Set A

HY-RS01192

ATP2A2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
ATP2A2 Human Pre-designed siRNA Set A contains three designed siRNAs for ATP2A2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ATP2A2 Human Pre-designed siRNA Set A ATP2A2 Human Pre-designed siRNA Set A

HY-161901

BC-1293	E1/E2/E3 Enzyme	Inflammation/Immunology
BC-1293 is an inhibitor for E3 ligase subunit FBXO24. BC-1293 disrupts the interaction between FBXO24 and aspartyl-tRNA synthetase (DARS2) and increases the level of DARS2. BC-1293 increases levels of IL-1β, IL-9, MIP-2, and TNF α, and exhibits immunostimulatory activity in mice .

HY-RS00410

ADRA1D Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
ADRA1D Human Pre-designed siRNA Set A contains three designed siRNAs for ADRA1D gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ADRA1D Human Pre-designed siRNA Set A ADRA1D Human Pre-designed siRNA Set A

HY-116982

BMY 7378 free base	Adrenergic Receptor 5-HT Receptor
BMY 7378 (free base) is a selective antagonist of α_1D-adrenoceptor (α_1D-AR). BMY 7378 (free base) binds to membranes expressing the cloned rat α_1D-AR with a >100-fold higher affinity (K_i=2 nM) than binding to either the cloned rat α_1A-AR (K_i=800 nM) or the hamster α_1B-AR (K_i=600 nM). BMY 7378 (free base) is a 5-HT_1A receptor partial agonist .

HY-101300R

Cirazoline hydrochloride (Standard) LD 3098 hydrochloride (StanDARd)	Reference Standards Adenosine Receptor	Neurological Disease
Cirazoline (hydrochloride) (Standard) is the analytical standard of Cirazoline (hydrochloride). This product is intended for research and analytical applications. Cirazoline hydrochloride (LD 3098 hydrochloride) is a potent competitive full?α1A-adrenergic receptor (α1A-AR) agonist (Ki=120 nM) and only a partial agonist at α1B-AR (Ki= 960 nM) and α1D-AR (Ki=660 nM) .

HY-148252

ADRA1D receptor antagonist 1 free base	Adrenergic Receptor	Endocrinology
ADRA1D receptor antagonist 1 (free base) (compound (R)-9s) is an orally active, potent and selective human α_1D-adrenoceptor (α_1D-AR) antagonist (K_i=1.6 nM). ADRA1D receptor antagonist 1 (free base) dose-dependently inhibits bladder contraction with an IC₃₀ value of 15 nM. ADRA1D receptor antagonist 1 (free base) can be used in studies of overactive bladder disorders such as urinary urgency, frequency and incontinence.

HY-10122S

Silodosin-d4	Isotope-Labeled Compounds Adrenergic Receptor	Endocrinology Cancer
Silodosin-d₄ is the deuterium labeled Silodosin. Silodosin (KAD 3213) is a potent, selective and orally active α1A-adrenergic receptor (α1A-AR) blocker. Silodosin exhibits high affinity for α1A-AR (Ki=0.036 nM), over 162-fold and 50-fold than for α1B-AR and α1D-AR with K_i values of 21 nM and 2.0 nM, respectively. Silodosin is an effective and well-tolerated agent, it can be used for the investigation of LUTS/BPH .

HY-10122R

Silodosin (Standard) KAD 3213 (StanDARd); KMD 3213 (StanDARd)	Reference Standards Adrenergic Receptor Bacterial	Endocrinology Cancer
Silodosin (Standard) is the analytical standard of Silodosin. This product is intended for research and analytical applications. Silodosin (KAD 3213; KMD 3213) is a potent, selective and orally active α1A-adrenergic receptor (α1A-AR) blocker. Silodosin exhibits high affinity for α1A-AR (K_i=0.036 nM), over 162-fold and 50-fold than for α1B-AR and α1D-AR with K_i values of 21 nM and 2.0 nM, respectively. Silodosin is an effective and well-tolerated agent, it can be used for the investigation of LUTS/BPH .

HY-101299BR

Dihydrexidine hydrochloride (Standard) DAR-0100 hydrochloride (StanDARd)	Dopamine Receptor Reference Standards	Neurological Disease
Dihydrexidine (hydrochloride) (Standard) is the analytical standard of Dihydrexidine (hydrochloride) (HY-101299B). This product is intended for research and analytical applications. Dihydrexidine hydrochloride (DAR-0100 hydrochloride) is a high potent, selective and full efficacy D1-like dopamine receptor (D1/D5) agonist, with an IC50 of 10 nM for D1 receptor. Dihydrexidine hydrochloride exhibits potent antiparkinsonian activity . Dihydrexidine hydrochloride can stimulate YAP phosphorylation .

HY-RS28063

Dars2 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Dars2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Dars2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Dars2 Rat Pre-designed siRNA Set A Dars2 Rat Pre-designed siRNA Set A

HY-100554R

BMY 7378 (Standard)	Adrenergic Receptor Reference Standards 5-HT Receptor	Cardiovascular Disease
BMY 7378 (Standard) is the analytical standard of BMY 7378 (HY-100554). This product is intended for research and analytical applications. BMY 7378 is a selective antagonist of α1D-adrenoceptor (α1D-AR). BMY 7378 binds to membranes expressing the cloned rat α1D-AR with a >100-fold higher affinity (Ki=2 nM) than binding to either the cloned rat α1A-AR (Ki=800 nM) or the hamster α1B-AR (Ki=600 nM). BMY 7378 is a 5-HT1A receptor partial agonist .

HY-118260

Phendioxan	Adrenergic Receptor	Endocrinology
Phendioxan is a compound with binding activity at the α(1)-adrenaline receptor subtype. The facilitated membrane diffusion of phendioxan is thought to be associated with improved α(1d)-AR affinity. Docking simulations of phendioxan at biological targets supported the stoichiometric analysis and revealed the importance of polar, electrostatic, hydrophobic, and shape effects of its phenoxy terminal orthogonal substituents on ligand binding .

Cat. No.	Product Name

HY-L165

Dopamine Receptor Compound Library	267 compounds
Dopamine receptor (DAR), widely distributed in the brain, plays a key role in regulating motor function, motivation, driving force and cognition. The role of DA is mediated by D1-type (D1, D5) and D2-type receptors (D2S, D2L, D3, D4), which are distributed in presynaptic, postsynaptic and extrasynaptic, projection neurons and interneurons. Each receptor has a different function. D1 and D5 receptors couple with G stimulation sites and activate Adenylyl cyclase. The activation of Adenylyl cyclase leads to the production of the second messenger cAMP, which leads to the production of protein kinase A (PKA), which leads to further transcription in the nucleus. D2 to D4 receptors are coupled to G inhibitory sites to inhibit adenylyl cyclase and activate potassium Ion channel. These receptors utilize phosphorylation cascades or direct membrane interactions to affect the functions of voltage-gated and neurotransmitter-gated channels, cytoplasmic enzymes, and transcription factors. Dopamine receptor plays an important role in daily life. MCE designs a unique collection of 267 small molecules related to dopamine receptor. It is a good tool for screening drugs from nervous system disease.

Dopamine Receptor Compound Library

267 compounds

Dopamine receptor (DAR), widely distributed in the brain, plays a key role in regulating motor function, motivation, driving force and cognition. The role of DA is mediated by D1-type (D1, D5) and D2-type receptors (D2S, D2L, D3, D4), which are distributed in presynaptic, postsynaptic and extrasynaptic, projection neurons and interneurons. Each receptor has a different function. D1 and D5 receptors couple with G stimulation sites and activate Adenylyl cyclase. The activation of Adenylyl cyclase leads to the production of the second messenger cAMP, which leads to the production of protein kinase A (PKA), which leads to further transcription in the nucleus. D2 to D4 receptors are coupled to G inhibitory sites to inhibit adenylyl cyclase and activate potassium Ion channel. These receptors utilize phosphorylation cascades or direct membrane interactions to affect the functions of voltage-gated and neurotransmitter-gated channels, cytoplasmic enzymes, and transcription factors. Dopamine receptor plays an important role in daily life.

MCE designs a unique collection of 267 small molecules related to dopamine receptor. It is a good tool for screening drugs from nervous system disease.

Cat. No.	Product Name	Type

HY-164152A

*ADC Control Human IgG1-Deruxtecan (DAR* 8)**	Fluorescent Dyes
ADC Control Human IgG1-Deruxtecan (DAR 8) is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-Deruxtecan and can inhibit DNA topoisomerase I. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E) .

HY-164152

*ADC Control Human IgG1-Deruxtecan (DAR* 4)**	Fluorescent Dyes
ADC Control Human IgG1-Deruxtecan (DAR 4) is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-Deruxtecan and can inhibit DNA topoisomerase I. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E) .

HY-136884

DAR-4M	Fluorescent Dyes
DAR-4M is a fluorescent indicator for nitric oxide (NO) based on the rhodamine chromophore (Ex/Em= 550/572 nm) .

Cat. No.	Product Name	Target	Research Area	Image

HY-P99542

Tusamitamab ravtansine SAR-408701; HuMAb2-3-SPDB-DM4	Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin	Cancer
Tusamitamab ravtansine (SAR-408701) is a targeted ADC against tumor cells expressing CEACAM5, composed of a humanized anti-CEACAM5 monoclonal antibody covalently linked to the potent cytotoxic agent, maytansinoid DM4 (HY-12454), via a cleavable linker. Tusamitamab ravtansine has an average drug-to-antibody ratio (DAR) of 3.8 .

HY-164152

*ADC Control Human IgG1-Deruxtecan (DAR* 4)**	Antibody-Drug Conjugates (ADCs) Topoisomerase	Cancer
ADC Control Human IgG1-Deruxtecan (DAR 4) is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-Deruxtecan and can inhibit DNA topoisomerase I. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E) .

HY-P99829

Cofetuzumab pelidotin PF-06647020; ABBV-647; h6M24-vc0101	Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin	Cancer
Cofetuzumab pelidotin (PF-06647020) is a PTK7-targeting ADC comprising a humanized anti-PTK7 mAb (hu6M024, IgG1) joined to an auristatin microtubule inhibitor payload, auristatin-0101 (Aur0101; HY-12522), by a cleavable valine-citrulline (vc)-based linker. Cofetuzumab pelidotin has a DAR of 4. Cofetuzumab pelidotin binds to cell-surface PTK7 with an EC₅₀ of 1153 pM by flow cytometry. Cofetuzumab pelidotin has the potential for solid tumors research .

HY-141599

Camidanlumab tesirine ADCT 301	Antibody-Drug Conjugates (ADCs) Interleukin Related	Cancer
Camidanlumab tesirine (ADCT 301) is an ADC comprising HuMax-TAC, a human IgG1 mAb directed against human CD25, stochastically conjugated through a dipeptide cleavable linker to a pyrrolobenzodiazepine (PBD) dimer warhead. Camidanlumab tesirine has a drug–antibody ratio (DAR) of 2.3. Camidanlumab tesirine binds human CD25 with picomolar affinity. Camidanlumab tesirine has highly potent and selective cytotoxicity against a panel of CD25-expressing human lymphoma cell lines .

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P72094

	ATP2A2 Protein, Human (His) Atp2a2; ATP2B; ATPase Ca++ transporting cardiac muscle slow twitch 2; Calcium pump 2; ATPase 2	Human	E. coli
	The ATP2A2 protein is a magnesium-dependent enzyme that hydrolyzes ATP and transfers calcium from the cytoplasm to the sarcoplasmic reticulum. It participates in autophagy during starvation and interacts with VMP1 to achieve ER isolating membrane contact. ATP2A2 Protein, Human (His) is the recombinant human-derived ATP2A2 protein, expressed by E. coli , with N-6*His labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-10122S

Silodosin-d4

Silodosin-d₄ is the deuterium labeled Silodosin. Silodosin (KAD 3213) is a potent, selective and orally active α1A-adrenergic receptor (α1A-AR) blocker. Silodosin exhibits high affinity for α1A-AR (Ki=0.036 nM), over 162-fold and 50-fold than for α1B-AR and α1D-AR with K_i values of 21 nM and 2.0 nM, respectively. Silodosin is an effective and well-tolerated agent, it can be used for the investigation of LUTS/BPH .

Cat. No.	Product Name		Classification

HY-163099

P5(PEG24)-VC-PAB-Exatecan		Alkynes
P5 (PEG24)-VC-PAB-Exatecan is a TOP1 inhibitor payload with antibody-conjugation-dependent activity. Conjugation of P5 (PEG24)-VC-PAB-Exatecan with Trastuzumab (HY-P9907) generates a *DAR8* antibody-drug conjugate (ADCs) with antibody-like pharmacokinetic properties. P5 (PEG24)-VC-PAB-Exatecan induces S-phase and G2-M-phase cell cycle arrest, DNA damage and apoptosis in target-positive tumor cells, and releases damage-associated molecular patterns (DAMP) related to immunogenic cell death (ICD). The ADCs prepared from it exert bystander killing effects on non-target tumor cells. ADCs based on P5 (PEG24)-VC-PAB-Exatecan exhibit linker stability in vitro and in vivo, show in vivo efficacy, and can be used in research related to HER2-positive cancers .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: